China's Cellular Biomedicine spikes on early CAR-T data

Shanghai drug developer Cellular Biomedicine ($CBMG) reported some positive results from a small study of its in-development cancer immunotherapy, sending its shares up more than 15% on Friday. The company, working alongside Chinese PLA General Hospital, is developing an engineered T cell therapy, or CAR-T, to treat Hodgkin's lymphoma. In a trial on 7 patients with late-stage lymphoma, the treatment stabilized the disease in three subjects and charted a partial response in two of them, Cellular Biomedicine said. Release

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.